Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

(2010) G. G. Malouf et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma

(2009) S. Stacchiotti et al.   CLINICAL CANCER RESEARCH

Adult Xp11 Translocation Renal Cell Carcinoma Diagnosed by Cytogenetics and Immunohistochemistry

(2009) Y. Komai et al.   CLINICAL CANCER RESEARCH

A Case of Adult Metastatic Xp11 Translocation Renal Cell Carcinoma Treated Successfully With Sunitinib

(2009) Toni K. Choueiri et al.   Clinical Genitourinary Cancer

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Optimizing recent advances in metastatic renal cell carcinoma

(2009) Kevin D. Courtney et al.   Current Oncology Reports

Renal Translocation Carcinomas

(2008) Philippe Camparo et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course possible Xp11.2 translocation

(2008) Henry B. Armah et al.   PATHOLOGY

Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

(2007) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY